Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

An announcement made by the Swiss drugmaker Novartis AG (NVS: Quote) on Wednesday suggested about the late-breaking results omalizumab clearing all the primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria or CSU.

It is a chronic and debilitating form of hives with partial approved treatment options. GLACIAL is considered as the second of three pivotal Phase III studies. These studies conduct analysis about the efficacy and safety of omalizumab in CSU.

The result derived from the study supported supported the efficacy, safety and tolerability of omalizumab in patients with refractory CSU. It is a kind of chronic and debilitating skin disease with obstinate itch and hives.

Near about 40 percent of CSU patients were unsuccessful on ntihistamines. These include those who were taking the approved dose even for the fourth time. The doses, in terms of official regulations are currently available only for treatment for CSU.

However, Omalizumab is presently not at all approved or indicated for CSU. Supervision of the submissions for omalizumab in CSU is scheduled for later times in the current year. It is a collaborated effort of Novartis and Genentech, Inc.

The data was brought forward for the first time at the European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress 2013 in Milan which is located in Italy.


FrenchTribune Specials

WHO Urges India to regulate use of E-Cigarettes

E-cigarette market in India is growing at a rapid pace and to keep a check on their adoption, the World Health Organization (WHO) has raised serious concerns. WHO experts have added that the use of e-cigarettes is not less harmful compared to the traditional cigarettes.

In India, smoking devices are easily available through online...

Most Popular

Researchers Trying Different Approach to Prevent Falls among Elderly

To prevent falls in older adults, researchers at the...

Frills coming fast for a No-Frills Airline

Ryanair, an Irish low-cost airline, has announced a new...

‘The Honest Company’ is worth $1billion after 2 Years of Launch

According to the Wall Street Journal, The Honest Company...

Park board resolutions on cetaceans challenged by Vancouver Aquarium

On Wednesday, John Nightingale, CEO and president of...

Poll

Can Greece Come out of Economic Problems: